Sarepta Therapeutics News Releases http://investorrelations.sarepta.com/ Sarepta Therapeutics News Releases en Sarepta Therapeutics Announces First Quarter 2019 Financial Results and Recent Corporate Developments http://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-first-quarter-2019-financial CAMBRIDGE, Mass. , May 08, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the three months ended March 31, 2019 . “Having built out our multi-platform portfolio of genetic medicine Wed, 08 May 2019 16:05:00 -0400 Sarepta Therapeutics News Releases 18491 Sarepta Announces Agreement with Nationwide Children’s Hospital for Rights to its Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A, the Most Common Form of Limb-Girdle Muscular Dystrophy http://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-agreement-nationwide-childrens-hospital-0 --Expands pipeline with 6 th investigational gene therapy for Limb-girdle muscular dystrophy-- --Furthers the Company’s commitment to finding treatments for neuromuscular conditions-- CAMBRIDGE, Mass. , May 08, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. Wed, 08 May 2019 08:30:00 -0400 Sarepta Therapeutics News Releases 18481 Sarepta Therapeutics to Announce First Quarter 2019 Financial Results and Recent Corporate Developments on May 8, 2019 http://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announce-first-quarter-2019-financial CAMBRIDGE, Mass. , May 01, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2019 financial results after the Nasdaq Global Market closes on Wednesday, May 8, 2019 . Subsequently, at 4:30 p.m. Wed, 01 May 2019 16:30:00 -0400 Sarepta Therapeutics News Releases 18456 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) http://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-40 CAMBRIDGE, Mass. , April 30, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 30, 2019 , that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s Tue, 30 Apr 2019 18:00:00 -0400 Sarepta Therapeutics News Releases 18411 Sarepta Therapeutics’ Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Clinical Data has been Accepted for a Late-breaking Oral Presentation at the 2019 MDA Clinical and Scientific Conference http://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-gene-therapy-limb-girdle-muscular-dystrophy --Six additional poster presentations highlighting data from Sarepta’s RNA and gene therapy programs also accepted-- CAMBRIDGE, Mass. , April 08, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today stated that its Mon, 08 Apr 2019 08:30:00 -0400 Sarepta Therapeutics News Releases 18331 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) http://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-39 CAMBRIDGE, Mass. , March 29, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2019 , that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s Fri, 29 Mar 2019 18:00:00 -0400 Sarepta Therapeutics News Releases 18301 Sarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE Study http://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-positive-expression-results -- Interim analysis found statistically significant increase in dystrophin production as measured by western blot in casimersen-treated participants compared to baseline and placebo --      -- Based on positive results, Company intends to schedule a pre-NDA meeting with FDA and plans to submit an Thu, 28 Mar 2019 08:30:00 -0400 Sarepta Therapeutics News Releases 18286 Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program http://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-provide-update-duchenne-muscular-dystrophy CAMBRIDGE, Mass. , March 25, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that it will host a webcast and conference call at 8:00 a.m. Eastern Time (ET) on Monday, March 25, 2019 . Mon, 25 Mar 2019 07:30:00 -0400 Sarepta Therapeutics News Releases 18261 Sarepta Therapeutics Announces Pricing of $375.0 Million Public Offering of Common Stock http://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-pricing-3750-million-public CAMBRIDGE, Mass. , March 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has priced an underwritten public offering of an aggregate of 2,604,167 shares of its common stock at a price to the Tue, 05 Mar 2019 19:32:00 -0500 Sarepta Therapeutics News Releases 18231 Sarepta Therapeutics Announces Proposed $350,000,000 Public Offering of Common Stock http://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-proposed-350000000-public CAMBRIDGE, Mass. , March 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it is offering to sell, subject to market and other conditions, $350,000,000 in shares of its common stock in an Tue, 05 Mar 2019 16:02:00 -0500 Sarepta Therapeutics News Releases 18211